Glycopeptide Antibiotics Global Market Report 2024: Forecast to Reach $5.02 Billion by 2028 - Long-term Forecast to 2028 and 2033
25 janv. 2024 04h19 HE
|
Research and Markets
Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The "Glycopeptide Antibiotics Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The global glycopeptide antibiotics...
Global Pseudomonas Aeruginosa Infection Treatment Market Report 2024: A USD 4.07 Billion Market by 2034, with Novel Antibiotics and Combination Therapies Emerging
22 janv. 2024 05h18 HE
|
Research and Markets
Dublin, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The "Global Pseudomonas Aeruginosa Infection Treatment Market" report has been added to ResearchAndMarkets.com's offering. The global pseudomonas...
New Research Shows Link Between Air Pollution Levels and Antibiotic Resistance
09 oct. 2023 18h00 HE
|
Camfil USA
Riverdale, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Riverdale, NJ — Antibiotic resistance poses a major threat to public health, resulting in approximately 700,000 premature deaths worldwide annually....
Global Antibiotic Resistance Markets, 2023-2027: Beyond Antibiotics - Exploring Cutting-Edge Trends in AMR Solutions
05 oct. 2023 06h43 HE
|
Research and Markets
Dublin, Oct. 05, 2023 (GLOBE NEWSWIRE) -- The "Antibiotic Resistance Markets - Therapeutics by Pathogen and Therapy Type. With Situation Analysis, Executive & Investor Guides &...
OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update
10 août 2023 16h15 HE
|
OpGen, Inc.
Total revenue for the first half of 2023 was approximately $1.65 million, an increase of approximately 15% compared to approximately $1.44 million in the first half of 2022Signed FIND R&D...
OpGen to Provide Business Update and Financial Results for the Second Quarter 2023 on August 10th at 4:30 p.m. Eastern Time
03 août 2023 07h30 HE
|
OpGen, Inc.
ROCKVILLE, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its second quarter...
OpGen Subsidiary Ares Genetics Successfully Maintains Key Patent under Opposition in Europe
26 juin 2023 07h30 HE
|
OpGen, Inc.
Patent EP 3 332 028 B1 granted by the European Patent Office covers the identification and use of genomic variants for the diagnosis of antibiotic resistant bacteria.The opposition division of...
Antibiotics Global Market Report 2023: Significant Growth Potential of Cell Wall and Protein Inhibitor Drugs Bodes Well for Sector
23 mai 2023 04h18 HE
|
Research and Markets
Dublin, May 23, 2023 (GLOBE NEWSWIRE) -- The "Antibiotics: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. The global market for antibiotics was...
Healthcare Industry Veteran Jamie Condie Joins Selux Diagnostics' Board of Directors
14 févr. 2023 07h30 HE
|
Selux Diagnostics
BOSTON, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Selux Diagnostics, a biotech startup in Boston whose mission is to combat superbug infections and antimicrobial resistance (AMR), announced today that...
FDA Clears 'Selux NGP System' for Rapid Antibiotic Susceptibility Testing
19 janv. 2023 07h00 HE
|
Selux Diagnostics
BOSTON, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Selux Diagnostics, a biotech startup in Boston whose mission is to combat superbug infections and antimicrobial resistance (AMR), announced it has received...